LYT-200
- Generic Name
- LYT-200
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- PureTech
- Target Recruit Count
- 90
- Registration Number
- NCT05829226
- Locations
- 🇺🇸
Mass. General Hospital-Harvard, Boston, Massachusetts, United States
🇺🇸Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
🇺🇸Baptist Health South Florida-Miami Cancer Institute, Miami, Florida, United States
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- PureTech
- Target Recruit Count
- 80
- Registration Number
- NCT04666688
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath